Cardiol Therapeutics Inc. (CRDL)
NASDAQ: CRDL · Real-Time Price · USD
1.400
-0.050 (-3.45%)
Jul 8, 2025, 4:00 PM - Market closed
Cardiol Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Cardiol Therapeutics stock have an average target of 9, which predicts a 542.86% increase from the current stock price of 1.4.
Price Target: $9 (+542.86%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Jun 2, 2025.
Analyst Ratings
The average analyst rating for Cardiol Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $9 | Strong Buy | Initiates | $9 | +542.86% | Jun 2, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +542.86% | Apr 16, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +542.86% | Apr 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +542.86% | Feb 24, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +542.86% | Dec 18, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
2.30M
EPS This Year
-0.53
from -0.51
EPS Next Year
-0.77
from -0.53
Financial currency is CAD. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 4.7M | 32.6M | ||
| Avg | n/a | 2.3M | 18.8M | ||
| Low | n/a | n/a | 5.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 1,315.2% | ||
| Avg | - | - | 718.3% | ||
| Low | - | - | 151.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.48 | -0.57 | -0.19 | ||
| Avg | -0.53 | -0.77 | -0.19 | ||
| Low | -0.56 | -0.94 | -0.18 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.